• Nenhum resultado encontrado

[PDF] Top 20 Molecular-cytogenetic variant in chronic myeloid leukemia

Has 10000 "Molecular-cytogenetic variant in chronic myeloid leukemia" found on our website. Below are the top 20 most common "Molecular-cytogenetic variant in chronic myeloid leukemia".

Molecular-cytogenetic variant in chronic myeloid leukemia

Molecular-cytogenetic variant in chronic myeloid leukemia

... Chronic myeloid leukemia (CML) was the first neoplastic disease to be linked to a genetic abnormality and is the best studied molecular model of ... See full document

2

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

... Data are required to support this strategy, such as the determination of biomarkers leading to relapse. Nevertheless, the possibility of a second attempt of TKI dis- continuation after a first unsuccessful attempt ... See full document

8

Rev. Bras. Hematol. Hemoter.  vol.35 número2

Rev. Bras. Hematol. Hemoter. vol.35 número2

... developed in this study was successfully validated and is being eficiently used to measure imatinib concentrations in samples from chronic myeloid leukemia patients to check treatment ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.37 número1

Rev. Bras. Hematol. Hemoter. vol.37 número1

... Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or ...resulting in the break-point cluster region- Abelson tyrosine kinase ... See full document

4

Clinics  vol.70 número8

Clinics vol.70 número8

... 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase ...the chronic phase patients (n=18), 89% achieved a complete hematologic ... See full document

6

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

... were in chronic ...years) in patients who were still on treatment (IFN-ON) and ...(4.8–10.8) in patients who had discontinued therapy (IFN-OFF, table 1). In IFN-OFF patients, the median ... See full document

12

Einstein (São Paulo)  vol.9 número2

Einstein (São Paulo) vol.9 número2

... acute myeloid leukemia in ...acute myeloid leukemia and perform bone marrow ...acute myeloid leukemia treated at the said centers between 2005 and ...and ... See full document

5

Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome

Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome

... seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia ...the molecular basis of these myeloid disorders cannot be completely ...(LOH) in 44 patients (18 MDS and 26 ... See full document

5

Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia

Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia

... particularly leukemia, show their potential as targets of smart nanomaterials and how much these diseases would benefit from a more personalized approach than current diagnostics and treatment ...foremost, ... See full document

220

Rev. Bras. Hematol. Hemoter.  vol.27 número3

Rev. Bras. Hematol. Hemoter. vol.27 número3

... Chronic Myeloid Leukemia (CML) is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 (Philadelphia ...late chronic phase resistant or intolerant to ... See full document

7

An uneventful pregnancy and delivery in a patient with chronic myeloid leukemia

An uneventful pregnancy and delivery in a patient with chronic myeloid leukemia

... platelets 3,60,000 cells/cumm (Figure-2). Ultrasonography of abdomen after delivery showed splenomegaly. Bone marrow examination revealed hypercellular bone marrow with increased granulopoiesis and 2 % blasts. ... See full document

2

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

... vary in their effects on the sensitivity to standard doses and dose escalations of imatinib and as well as to other TKIs [3,6–7,13,36– ...or in combination with F311L and/or M351T) did not respond to ... See full document

9

Rev. Bras. Hematol. Hemoter.  vol.33 número6

Rev. Bras. Hematol. Hemoter. vol.33 número6

... mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to ... See full document

6

The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia

The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia

... cells in metaphase, the point at which the chromosomes are more ...variants in CML may present fused genes that can be detected by molecular techniques such as FISH or polymerase chain reaction (PCR) ... See full document

9

Rev. Bras. Hematol. Hemoter.  vol.30 número4

Rev. Bras. Hematol. Hemoter. vol.30 número4

... Chronic myeloid leukemia (MLC) is characterized by the presence of the Philadelphia chromosome, the result of a reciprocal and balanced translocation between chromosomes 9 and 22, which is present ... See full document

2

A mutação JAK2 V617F e as síndromes mieloproliferativas.

A mutação JAK2 V617F e as síndromes mieloproliferativas.

... and chronic myeloid leukemia are considered classic myeloproliferative disorders and share common clinical and biological ...of chronic myeloid leukemia is shown to be the ... See full document

8

Arq. NeuroPsiquiatr.  vol.74 número10

Arq. NeuroPsiquiatr. vol.74 número10

... his study was approved by the HC-UFPR review board. A retrospective, longitudinal study was conducted utilizing CSF laboratory results from the data iles of the clinical pa- thology laboratory of the General Hospital – ... See full document

7

Resistance: First Case Report

Resistance: First Case Report

... worse molecular response and to imatinib treatment failure, even after increase of the dose in 2011, when the patient was referred to our ...of chronic-phase CML is preferred, and although no evi- ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.36 número1

Rev. Bras. Hematol. Hemoter. vol.36 número1

... Self-reporting, in which patients are requested to recollect how reliably they complied with their treatment regimen, has been criticized as too subjective, with a propensity for patients to over-report rates of ... See full document

6

Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL

Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL

... se quer à conformação activa, quer à inactiva da cinase Abl, necessita de poucos pontos de contacto com a Abl e tem mais afinidade para o domínio da cinase Abl que o IM. A actividade do dasatinib contra várias mutações ... See full document

7

Show all 10000 documents...